Allarity Therapeutics, Inc.: This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Copenhagen ,Køavn ,Denmark ,Mansoor Raza Mirza ,Kathleenn Moore ,Allarity Therapeuticsview ,Thomas Pedersen ,Thomas Jensen ,Clinical Research ,Department Of Oncology At Copenhagen University Hospital ,Stephenson Cancer Center ,Salarius Pharmaceuticals ,University Of Oklahoma College Medicine ,National Cancer Institute ,Allarity Therapeutics Inc ,Allarity Therapeutics ,Copenhagen University Hospital ,Scientific Advisory Board ,Principal Investigator ,Gynecologic Oncology ,Oklahoma College ,Associate Director ,Stephenson Cancer ,Cancer Institute ,Allarity ,Herapeutics ,This ,Combination ,Therapy ,Would ,Help ,Change ,Dancer ,Treatment ,Lake ,Keeper ,Book ,Into ,Trial ,